ranitidin ratiopharm 150 mg
ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 150 mg
ranitidin ratiopharm 300 mg
ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 300 mg
zantac 150 mg
glaxosmithkline as - ranitidinhydroklorid - brusetablett - 150 mg
zantac 25 mg/ ml
glaxosmithkline as - ranitidinhydroklorid - injeksjonsvæske, oppløsning - 25 mg/ ml
zantac 150 mg
glaxosmithkline as - ranitidinhydroklorid - tablett - 150 mg
ranitidin ratiopharm 75 mg
ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 75 mg
enalapril comp ratiopharm 20 mg / 12.5 mg
ratiopharm gmbh - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg
zestoretic 20 mg / 12.5 mg
atnahs pharma netherlands b.v. - lisinoprildihydrat / hydroklortiazid - tablett - 20 mg / 12.5 mg
axura
merz pharmaceuticals gmbh - memantinhydroklorid - alzheimers sykdom - andre anti-demens medisiner - behandling av pasienter med moderat til alvorlig alzheimers sykdom.
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).